Abstract 1826P
Background
The global incidence of breast cancer is increasing, highlighting the need for attention not only to treatment but also to long-term survivorship issues. Osteoporosis, an age-related bone disorder, presents a significant concern for patients with breast cancer due to its potential impact on morbidity and mortality. This Korean nationwide cohort study aimed to investigate the occurrence and risk factors of osteoporosis among patients with breast cancer, with a specific focus on gender disparities.
Methods
Using data from the Korean National Health Insurance claim database, we identified individuals diagnosed with ductal carcinoma in situ or breast cancer as their primary diagnosis between 2009 and 2015. Patients diagnosed with osteoporosis were determined based on ICD-10 codes (International Classification of Disease) and medication prescriptions. Propensity score matching was performed to minimize confounding variables.
Results
Among 299 male and 80362 female breast cancer patients, a higher prevalence of osteoporosis was observed in females (n=13423(16.7%) vs n=15(5.0%)). Endocrine therapy was associated with an increased risk of osteoporosis, particularly among females (HR 6.37, 95%CI, 3.74-10.89, p<0.001). Age, steroid medication use, and comorbidity burden were also identified as significant risk factors for osteoporosis. Adjusting other variables, females diagnosed with osteoporosis had a higher incidence of only hip or vertebral fractures compared to males (HR 3.96, 95%CI, 1.24-12.64, p=0.020). While overall fracture incidence was higher in males before matching, gender differences were not significant after propensity score matching.
Conclusions
In conclusion, our study highlights the importance of proactive screening and management of osteoporosis in breast cancer patients, with a focus on gender-specific risk factors. These findings emphasize the necessity of comprehensive bone health assessment and preventive measures to improve long-term outcomes and quality of life for breast cancer survivors. Further research is warranted to elucidate the underlying mechanisms of gender differences in osteoporosis risk and evaluate the effectiveness of targeted interventions in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1843P - Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
Presenter: Davide Smussi
Session: Poster session 12
1844P - 3-year experience of the Belgian multidisciplinary immunotoxicity board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO)
Presenter: Marthe Verhaert
Session: Poster session 12
1845P - The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Zac Coyne
Session: Poster session 12
1846P - Social determinants of health in studies assessing toxicities associated with immune checkpoint inhibitor treatment: A systematic review
Presenter: Sofia Georgopoulou
Session: Poster session 12
1847P - Safety and efficacy of immune checkpoint inhibitors in patients over 85 years: ICIPO85 study
Presenter: MYRTILLE THOMAS
Session: Poster session 12
1848P - Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience
Presenter: Onur Bas
Session: Poster session 12
1849P - Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 12
1850P - Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Presenter: Jesús Peña-Lopez
Session: Poster session 12
1851P - Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis
Presenter: Taha Koray Sahin
Session: Poster session 12
1852P - The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Presenter: Poorni Jaganathan
Session: Poster session 12